Trial Profile

Phase II Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Apr 2025 According to a Biodexa Pharmaceuticals media release, data readout is expected in the first half of 2025.
26 Apr 2024 According to a Biodexa Pharmaceuticals media release, company entered into a definitive agreement with Rapamycin Holdings Inc. (d/b/a Emtora Biosciences) for the rights to eRapa under an exclusive, worldwide license (with the ability to grant sublicenses) to develop, manufacture, commercialize and otherwise advance the clinical potential of eRapa. The Phase 2 study in NMI Bladder Cancer supported by $3 million grant from National Cancer Institute, part of the National Institutes of Health
26 Apr 2024 According to a Biodexa Pharmaceuticals media release, Phase 2 study in Non-muscle Invasive Bladder Cancer expected to read-out in Q2 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com